Pre-exposure (PrEP)
Pre-exposure Prophylaxis (PrEP)
New Advocacy Group Wants to Improve Feasibility of PrEP for U.S. Women
- Details
- Category: HIV Prevention
- Published on Wednesday, 20 March 2013 00:00
- Written by Anna Forbes
Following disappointing results from the VOICE trial released at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta, a new U.S. Women and PrEP Working Group has called on the federal government to help American women use antiretroviral pre-exposure prophylaxis (PrEP) safely and effectively. But the AIDS Healthcare Foundation (AHF) responded by urging the Food and Drug Administration to rescind its approval of Truvada (tenofovir/emtricitabine) for HIV prevention.
CROI 2013: Monthly Injectable and Tenofovir Vaginal Ring Protect Monkeys against Infection
- Details
- Category: HIV Prevention
- Published on Wednesday, 06 March 2013 00:00
- Written by Gus Cairns
A long-acting injectable integrase inhibitor (GSK1265744) protected male macaque monkeys from rectal infection with an HIV-like virus, while a vaginal ring containing tenofovir prevented infection of female monkeys, researchers reported at the this week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
Truvada PrEP Demonstration Project Debuts in San Francisco
- Details
- Category: HIV Prevention
- Published on Friday, 28 September 2012 00:00
- Written by Liz Highleyman
The San Francisco Department of Public Health's new pre-exposure prophylaxis demonstration project opened for enrollment at City Clinic on Friday, September 21. Men who have sex with men (MSM) and transgender women with ongoing risk of HIV infection are eligible to receive Truvada PrEP for up to 1 year.
Pre-exposure prophylaxis, better known as PrEP, refers to use of antiretroviral drugs prior to unprotected sex or other exposures to prevent HIV from taking hold in the body. Most PrEP research has looked at an oral combination of tenofovir plus emtricitabine, the drugs in Truvada. Already a widely used component of HIV treatment, the U.S. Food and Drug Administration approved Truvada for PrEP on July 16, 2012.
CROI 2013: VOICE Trial's Disappointing Result Poses Big Questions for PrEP
- Details
- Category: HIV Prevention
- Published on Monday, 04 March 2013 00:00
- Written by Gus Cairns
The failure of one of the largest trials yet conducted of HIV drug-based prevention methods poses questions for how to turn vaginal microbicides and oral pre-exposure prophylaxis (PrEP) into methods people can actually use, the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta heard today.
ICAAC 2012: Novel NNRTI MK-1439 Shows Potent Activity, Distinct Resistance Profile
- Details
- Category: HIV Treatment
- Published on Wednesday, 26 September 2012 00:00
- Written by Liz Highleyman
The novel non-nucleoside reverse transcriptase inhibitor (NNRTI) MK-1439 exhibited good activity against a variety of HIV subtypes and maintained its potency against most common NNRTI-resistant viruses, researchers reported at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) this month in San Francisco. 
More Articles...
- Analysis Confirms Link Between PrEP Adherence and Reduced HIV Risk, Estimates Effective Dosing
- ICAAC 2012: Long-acting Integrase Inhibitor S/GSK1265744 Active Against HIV Subtypes
- CDC Issues PrEP Guidance for Prevention of Heterosexual HIV Transmission
- AIDS 2012: Long-acting HIV Integrase Inhibitor S/GSK1265744 May Allow Monthly Dosing
Web Design and Development by